Business Context and Reporting Period
Company: Launch One Acquisition Corp. (SPAC)
Filing Date: June 25, 2025
Event: Entry into a Business Combination Agreement (BCA) with Minovia Therapeutics Ltd. (Minovia), an Israeli biopharmaceutical company. The transaction involves a merger structure where Minovia and Launch One will become wholly-owned subsidiaries of a new public entity, Pubco (MitoUS One Ltd.), listed on Nasdaq.
Key Financial Metrics and Transaction Terms
Transaction Consideration:
- Base Merger Consideration: $180 million in Pubco ordinary shares.
- Additional Consideration: Aggregate net cash proceeds received by Minovia from financing activities between signing and closing, valued at the redemption price paid to SPAC shareholders.
- Valuation Basis: Shares are valued at the "Redemption Price" (price paid to SPAC public shareholders electing to redeem).
Earnout Provisions:
- Value: Up to $57.5 million in Pubco ordinary shares.
- Triggers (within 5 years):
- Pubco stock trades at a 5-day VWAP of at least $11.50 per share.
- Commencement of a Phase 3 clinical trial for Minovia's Pearson syndrome program (or FDA approval of a BLA without Phase 3).
- Acceleration: Earnout accelerates upon a change-in-control transaction if the implied share price exceeds $11.50.
Financing Requirements:
- Bridge Financing: Minimum $5 million at a $120 million pre-money valuation (to be consummated within 30 days).
- Additional Transaction Financing: Minimum $18 million in aggregate proceeds.
- Minimum Cash Condition: Closing requires at least $23 million in cash and cash equivalents (including trust account funds, financing proceeds, less expenses and liabilities).
Financial Statements: The filing does not provide specific revenue, profit, or cash flow figures for Minovia or Launch One. Minovia is required to deliver PCAOB audited financial statements for fiscal years ended Dec 31, 2023 and 2024, and reviewed interim statements for the six months ended June 30, 2025.
Material Changes and Governance
Corporate Structure: Post-closing, Pubco will be a publicly traded company on Nasdaq. Launch One and Minovia will be subsidiaries.
Board Composition: The Pubco board will consist of 8 directors:
- 5 designated by Minovia.
- 1 designated by the SPAC Sponsor.
- 2 designated by Alex Greystoke and Jon Bakhshi (contingent on payment of legal/audit expenses and satisfaction of the Minimum Cash Condition).
Equity Plan: A new incentive equity plan will be adopted with awards equal to 10% of outstanding Pubco shares immediately after closing.
Lock-Up Agreements: Key Minovia security holders (officers, directors, and those owning >3% equity) are subject to a one-year lock-up, with early release provisions if the stock price exceeds $12.00 for 20 of 30 trading days after 150 days post-closing.
Guidance, Risks, and Contingencies
Conditions to Closing: The transaction is subject to customary conditions, including shareholder approvals (SPAC and Minovia), Nasdaq listing approval, SEC effectiveness of the Form F-4 registration statement, and the absence of a Material Adverse Effect.
Termination Rights:
- Outside Date: December 24, 2025.
- FTO Opinion: SPAC may terminate if a Freedom to Operate analysis indicates likely material infringement of third-party U.S. patents, unless a mitigation plan is accepted.
- Financing Failure: Either party may terminate if the $5 million Bridge Financing is not consummated within 30 days.
- Board Recommendation: Minovia may terminate if SPAC changes its board recommendation against the deal.
Risks and Contingencies:
- Redemptions: The Minimum Cash Condition depends on the level of shareholder redemptions from the SPAC trust account.
- Regulatory: Requires Israeli tax rulings and securities law rulings.
- Intellectual Property: Reliance on the FTO Opinion regarding U.S. patent infringement.
- Forward-Looking Statements: Management cautions that actual results may differ materially from projections regarding Minovia's clinical development and growth.
Investor Verification Checklist
- Redemption Levels: Verify the final redemption rate from the SPAC trust account to ensure the $23 million Minimum Cash Condition is met.
- Financing Status: Confirm the successful closing of the $5 million Bridge Financing and the $18 million Additional Transaction Financing.
- FTO Opinion: Review the outcome of the Freedom to Operate analysis regarding Minovia's technology and U.S. patent landscape.
- Shareholder Approval: Monitor the results of the SPAC and Minovia shareholder votes on the Business Combination Agreement.
- Financial Health: Review the PCAOB audited financial statements for Minovia (2023, 2024) and interim statements (H1 2025) once filed to assess burn rate and liquidity.
- Regulatory Approvals: Confirm receipt of necessary Israeli tax and securities rulings.